Zacks Investment Research on MSN

CHMP backs higher-dose Wegovy as Novo Nordisk seeks 2026 EU approval

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
inews.co.uk on MSN

Wegovy on the NHS ends after 24 months – meaning weight gain or going private

A spokesperson for Novo Nordisk, the manufacturer of Wegovy, said: “Wegovy is indicated for weight management, including ...
Zacks.com on MSN

NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

Novo’s High-Dose Wegovy Gets Green Light From EU Drug Panel

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

EU drugs regulator backs higher dose of Novo's Wegovy

Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.